Results 1 to 10 of about 2,231,197 (287)
Seminars in Thrombosis and Hemostasis, 2009 The complex formed between the procoagulant serine protease activated factor VII (FVII) and the membrane protein tissue factor, exposed on the vascular lumen upon injury, triggers the initiation of blood clotting. This review describes the clinical picture of FVII deficiency and provides information on diagnosis and management of the disease.
G. Mariani, BERNARDI, Francesco
openaire +5 more sources
Thromboembolism and Factor VII Defect [PDF]
Acta Haematologica, 1984 Antonio Girolami
openalex +4 more sources
Inhibitors to factor
Haemophilia, 2014 We performed a prospective study of FVII inhibitor occurrence in a large number of patients with FVII deficiency who had received replacement therapy for spontaneous or traumatic bleeding episodes, major or minor surgical interventions or prophylaxis.Inhibitor development was detected in 2.6% (3/115) of patients, but the incidence of de novo inhibitors
Batorova A +11 more
openaire +3 more sources
Blood Coagulation & Fibrinolysis, 2002 As yet, there have been neither systematic reviews nor reports of randomized, controlled trials involving factor VII (FVII) deficiency. Hence, a picture of this disorder can only be drawn by reviewing and summarizing the data that is available. This article provides an overview of the understanding of this rare, inherited disorder of coagulation.
openaire +5 more sources
Factor VII verona coagulation disorder: double heterozygosis with an abnormal factor VII and heterozygous factor VII deficiency [PDF]
Blood, 1977 A family with a peculiar defect of factor VII is described. The propositi, a brother and sister, were born of a nonconsanguineous marriage and presented a mild to moderate bleeding tendency since childhood (epistaxis, excessive bleeding after tooth extraction).
G Patrassi +4 more
openaire +4 more sources
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Pharmacokinetics of Factor VII
Blood, 2011 Abstract Abstract 2259 Introduction: In Congenital Bleeding Disorders (CBD), efficacy of Replacement Therapy (RT) can be indirectly measured on the basis of pharmacokinetic (PK) methods.
Morfini,M +7 more
openaire +3 more sources
Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. [PDF]
Journal of Biological Chemistry, 1981 A procedure has been developed for the isolation of human Factor VII to apparent homogeneity as judged by the analytical disc electrophoretic system of Davis (pH 8.9) and by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The isolated procedure involves adsorption of Factor VII onto barium citrate, ammonium sulfate fractionation, DEAE ...
S P Bajaj +2 more
openaire +2 more sources
Quantum Cosmology for the General Bianchi Type II, VI(Class A) and VII(Class A) vacuum geometries [PDF]
, 2001 The canonical quantization of the most general minisuperspace actions --i.e. with all six scale factor as well as the lapse function and the shift vector present-- describing the vacuum type II, VI and VII geometries, is considered.
C Brans +11 more
core +7 more sources
Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? [PDF]
, 2003 BACKGROUND Conventional hormone replacement therapy (HRT) containing conjugated equine oestrogen (CEE) and medroxyprogesterone acetate (MPA) increases triglyceride, C- reactive protein (CRP) and coagulation Factor VII concentrations, potentially ...
Alan J. Jaap +46 more
core +1 more source